Quick Answer
Alzamend Neuro, Inc. reported Net Income of -$4.51 million for fiscal year 2025.
Alzamend Neuro, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$4.51M +54.6% |
-$9.95M +33.1% |
-$14.88M -20.4% |
-$12.36M -145.0% |
-$5.05M -14.4% |
-$4.41M |
| Diluted EPS | -$11.32 +91.4% |
-$132.33 -478.1% |
-$22.89 -16250.0% |
-$0.14 | — | — |
| Total Assets | $4.60M +628.8% |
$631.6K -89.3% |
$5.92M -59.2% |
$14.52M +398.4% |
$2.91M +60.6% |
$1.81M |
| Cash and Equivalents | $3.95M +950.0% |
$376.0K -92.7% |
$5.14M -63.4% |
$14.06M +629.0% |
$1.93M +2036.9% |
$90.3K +111.9% |
| Stockholders Equity | $3.97M +253.0% |
-$2.59M -185.2% |
$3.05M -77.2% |
$13.35M +563.3% |
$2.01M +145.0% |
$821.7K +159.3% |
| R&D Expense | $1.41M -78.1% |
$6.46M -13.3% |
$7.45M +43.2% |
$5.20M +296.8% |
$1.31M +22.6% |
$1.07M |
| Operating Income | -$4.50M +54.7% |
-$9.94M +33.2% |
-$14.87M -20.7% |
-$12.32M -148.8% |
-$4.95M -11.9% |
-$4.42M |
| Shares Outstanding | 778,733 +918.7% |
76,444 -88.2% |
646,267 -99.3% |
95.48M +41.6% |
67.43M +4.1% |
64.76M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | October 31, 2025 | -$1.00M | +26.5% | +63.0% |
| Diluted EPS | October 31, 2025 | -$0.30 | +91.7% | +76.6% |
| Total Assets | October 31, 2025 | $5.09M | +1.7% | -19.5% |
| Cash and Equivalents | October 31, 2025 | $4.45M | +8.7% | -20.8% |
| Stockholders Equity | October 31, 2025 | $4.37M | +16.6% | -18.1% |
| R&D Expense | October 31, 2025 | $176.3K | -43.3% | -89.9% |
| Operating Income | October 31, 2025 | -$998.1K | +26.5% | +63.0% |
| Shares Outstanding | October 31, 2025 | 3.80M | -27.3% | +21.1% |
- Alzamend Neuro, Inc. reported Net Income of -$4.51 million for fiscal year 2025.
- Alzamend Neuro, Inc. showed an increase of +54.6% in Net Income compared to the prior fiscal year.
- Alzamend Neuro, Inc. reported Diluted EPS of $11.32 per share (loss) for fiscal year 2025.
- Alzamend Neuro, Inc. showed an increase of +91.4% in Diluted EPS compared to the prior fiscal year.
- Alzamend Neuro, Inc. reported Total Assets of $4.60 million for fiscal year 2025.
- Alzamend Neuro, Inc. showed an increase of +628.8% in Total Assets compared to the prior fiscal year.
- Alzamend Neuro, Inc. reported Cash and Equivalents of $3.95 million for fiscal year 2025.
- Alzamend Neuro, Inc. showed an increase of +950.0% in Cash and Equivalents compared to the prior fiscal year.
- Alzamend Neuro, Inc. reported Stockholders Equity of $3.97 million for fiscal year 2025.
- Alzamend Neuro, Inc. showed an increase of +253.0% in Stockholders Equity compared to the prior fiscal year.
- Alzamend Neuro, Inc. reported R&D Expense of $1.41 million for fiscal year 2025.
- Alzamend Neuro, Inc. showed a decrease of -78.1% in R&D Expense compared to the prior fiscal year.
- Alzamend Neuro, Inc. reported Operating Income of -$4.50 million for fiscal year 2025.
- Alzamend Neuro, Inc. showed an increase of +54.7% in Operating Income compared to the prior fiscal year.
- Alzamend Neuro, Inc. reported Shares Outstanding of 778.7 thousand shares for fiscal year 2025.
- Alzamend Neuro, Inc. showed an increase of +918.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: